Virtus ETF Advisers’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $363K | Buy |
|
|||||
|
2025
Q2 | $81.7K | Sell |
|
|||||
|
2025
Q1 | $286K | Sell |
|
|||||
|
2024
Q4 | $376K | Buy |
|
|||||
|
2024
Q3 | $278K | Hold |
|
|||||
|
2024
Q2 | $333K | Sell |
|
|||||
|
2024
Q1 | $433K | Buy |
|
|||||
|
2023
Q4 | $354K | Sell |
|
|||||
|
2023
Q3 | $363K | Sell |
|
|||||
|
2023
Q2 | $344K | Buy |
|
|||||
|
2023
Q1 | $262K | Buy |
|
|||||
|
2022
Q4 | $303K | Sell |
|
|||||
|
2022
Q3 | $274K | Buy |
|
|||||
|
2022
Q2 | $248K | Sell |
|
|||||
|
2022
Q1 | $422K | Hold |
|
|||||
|
2021
Q4 | $383K | Sell |
|
|||||
|
2021
Q3 | $441K | Sell |
|
|||||
|
2021
Q2 | $488K | Sell |
|
|||||
|
2021
Q1 | $651K | Buy |
|
|||||
|
2020
Q4 | $624K | Buy |
|
|||||
|
2020
Q3 | $490K | Buy |
|
|||||
|
2020
Q2 | $587K | Sell |
|
|||||
|
2020
Q1 | $461K | Sell |
|
|||||
|
2019
Q4 | $620K | Sell |
|
|||||
|
2019
Q3 | $743K | Sell |
|
|||||
|
2019
Q2 | $814K | Sell |
|
|||||
|
2019
Q1 | $940K | Buy |
|
|||||
|
2018
Q4 | $592K | Buy |
|
|||||
|
2018
Q3 | $962K | Buy |
|
|||||
|
2018
Q2 | $717K | Sell |
|
|||||
|
2018
Q1 | $1.07M | Sell |
|
|||||
|
2017
Q4 | $1.06M | Sell |
|
|||||
|
2017
Q3 | $1.44M | Hold |
|
|||||
|
2017
Q2 | $1.08M | Buy |
|
|||||
|
2017
Q1 | $280K | Buy |
|
|||||
|
2016
Q4 | $227K | Buy |
|
|||||
|
2016
Q3 | $270K | Hold |
|
|||||
|
2016
Q2 | $242K | Buy |
|
|||||
|
2016
Q1 | $188K | Buy |
|